Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.61 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30513304 | 1.00 | ESR1 (0.61) | ESR1ESR2DRD2DRD3DRD4 | |
| SCHEMBL9749055 | 0.86 | ESR1 (0.61) | ESR1ESR2DRD2DRD3DRD4 | |
| SCHEMBL5541364 | 0.81 | TDP1 (0.60) | ESR1ESR2BRD4CREBBPTDP1 | |
| SCHEMBL634750 | 0.80 | ESR1 (0.68) | ESR1ESR2DRD2DRD3DRD4 | |
| SCHEMBL18743290 | 0.80 | CREBBP (0.44) | ESR1ESR2BRD4CREBBPTDP1 | |
| SCHEMBL11926950 | 0.80 | CREBBP (0.44) | ESR1ESR2BRD4CREBBPTDP1 | |
| SCHEMBL23940440 | 0.79 | TDP1 (0.38) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL8188224 | 0.79 | DRD2 (0.51) | ESR1ESR2DRD2DRD3OPRK1 | |
| SCHEMBL17321070 | 0.79 | PBRM1 (0.49) | ESR1ESR2TDP1 | |
| SCHEMBL19188071 | 0.79 | TDP1 (0.38) | ESR1ESR2DRD2DRD3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103462817-A | Oral care composition comprising a phenolic compound and antioxidant vitamins and vitamin derivatives | COLGATE PALMOLIVE CO | 2013-12-25 | — | — | CN | claimed |
| CN-101111288-A | Oral care compositions containing phenolic compounds and antioxidant vitamins and vitamin derivatives | COLGATE PALMOLIVE CO (US) | 2008-01-23 | — | — | CN | claimed |
| EP-1817081-A2 | ORAL CARE COMPOSITION COMPRISING A PHENOLIC COMPOUND AND ANTIOXIDANT VITAMINS AND VITAMIN DERIVATIVES | Colgate-Palmolive Company (US) | 2007-08-15 | — | — | EP | claimed |
| WO-2006060145-A2 | ORAL CARE COMPOSITION COMPRISING A PHENOLIC COMPOUND AND ANTIOXIDANT VITAMINS AND VITAMIN DERIVATIVES | COLGATE-PALMOLIVE COMPANY (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060120975-A1 | Oral care composition comprising a phenolic compound and antioxidant vitamins and vitamin derivatives | COLGATE-PALMOLIVE COMPANY | 2006-06-08 | — | — | US | claimed |
| EP-3772975-A1 | NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS | DSM IP Assets B.V. (NL) | 2021-02-17 | — | — | EP | disclosed |
| US-20210030022-A1 | NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS | DSM IP ASSETS B.V. (NL) | 2021-02-04 | — | — | US | disclosed |
| WO-2019185894-A1 | NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS | DSM IP ASSETS B.V. (NL) | 2019-10-03 | — | — | WO | disclosed |
| WO-2019185891-A1 | NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS | DSM IP ASSETS B.V. (NL) | 2019-10-03 | — | — | WO | disclosed |
| US-9763952-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9539260-B2 | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | NOVARTIS AG (CH) | 2017-01-10 | — | — | US | disclosed |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| WO-2006060145-A2 | ORAL CARE COMPOSITION COMPRISING A PHENOLIC COMPOUND AND ANTIOXIDANT VITAMINS AND VITAMIN DERIVATIVES | COLGATE-PALMOLIVE COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2005099484-A1 | WATER CONTINUOUS PRODUCT COMPRISING STEROL OR STANOLESTER AND A TOCOPHEROL | UNILEVER N.V. (NL) | 2005-10-27 | — | — | WO | disclosed |
| JP-2000026270-A | SKIN PREPARATION FOR EXTERNAL USE CONTAINING RETINOIDS | ISEHAN:KK | 2000-01-25 | — | — | JP | disclosed |
| EP-0230475-B1 | NOVEL UREA DERIVATIVES, PROCESSES FOR PRODUCTION THEREOF AND HERBICIDE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-4838924-A | NONPHYTOTOXIC | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-06-13 | — | — | US | disclosed |
| EP-0129906-A1 | Phenoxyalkoxy-3,4-dihydro-2H-1-benzopyran derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1985-01-02 | — | — | EP | disclosed |
| US-3951664-A | Light-sensitive material having developers embedded therein | AGFA-GEVAERT, A.G. (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3933507-A | LIGHT INSENSITIVE SILVER SALT, POLYMETHINE SENSITIZER | AGFA-GEVAERT, A.G. (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030022-A1 | NOVEL USE OF SUBSTITUTED CHROMAN-6-OLS | KMO, FFAR3, ACOX3 | ESR1 2896/4885ESR2 2334/4885DRD2 870/4885 |
| US-20160106753-A1 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives | PDXK, PDK1, DPYD | ESR1 1118/4885ESR2 2251/4885DRD2 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.